[Current status of the problem of disseminated sclerosis].
Kanareĭkin
K F
KF
Bakhur
V T
VT
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000818:Animals; D000956:Antigens, Viral / Q000276:immunology; D003131:Combined Modality Therapy; D003711:Demyelinating Diseases / Q000276:immunology; D003937:Diagnosis, Differential; D004782:Environmental Health; D000939:Epitopes / Q000276:immunology; D006680:HLA Antigens / Q000032:analysis / Q000276:immunology; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D066298:In Vitro Techniques; D050356:Lipid Metabolism; D009103:Multiple Sclerosis / Q000209:etiology* / Q000276:immunology / Q000628:therapy; D009902:Optic Neuritis / Q000175:diagnosis / Q000276:immunology; D010375:Pedigree; D012306:Risk; D012897:Slow Virus Diseases / Q000150:complications; D013601:T-Lymphocytes / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology; D014780:Viruses / Q000472:pathogenicity
D000276:Adjuvants, Immunologic; D000956:Antigens, Viral; D000939:Epitopes; D006680:HLA Antigens
Sovremennoe sostoianie problemy rasseiannogo skleroza.